Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities.
| Title: | Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. |
|---|---|
| Authors: | Cardin S; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Bilodeau M; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Roussy M; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Department of Biomedical Sciences.; Faculty of Medicine.; Aubert L; Cell Signaling and Proteomics Research Unit, and.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Milan T; Laboratory for High-Throughput Biology, Institute for Research in Immunology and Cancer, Montréal, QC, Canada.; Jouan L; Integrated Centre for Pediatric Clinical Genomics, CHU Sainte-Justine Research Center, Montréal, QC, Canada.; Rouette A; Integrated Centre for Pediatric Clinical Genomics, CHU Sainte-Justine Research Center, Montréal, QC, Canada.; Laramée L; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Gendron P; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Bioinformatics Platform, Université de Montréal, Montréal, QC, Canada.; Duchaine J; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Decaluwe H; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Spinella JF; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Mourad S; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Couture F; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Sinnett D; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Haddad É; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Department of Microbiology, Infectiology and Immunology, CHU Sainte-Justine, Montréal, QC, Canada.; Landry JR; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Streamline Genomics, Montréal, QC, Canada.; Ma J; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.; Humphries RK; British Columbia Cancer Agency, Vancouver, BC, Canada.; Roux PP; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Laboratory for High-Throughput Biology, Institute for Research in Immunology and Cancer, Montréal, QC, Canada.; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.; Hébert J; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Division of Hematology, and.; Québec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital, Montréal, QC, Canada; and.; Gruber TA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.; Wilhelm BT; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Laboratory for High-Throughput Biology, Institute for Research in Immunology and Cancer, Montréal, QC, Canada.; Cellot S; Pediatric Hematology-Oncology Division, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine Research Center, Montréal, QC, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.; Québec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital, Montréal, QC, Canada; and. |
| Source: | Blood advances [Blood Adv] 2019 Nov 12; Vol. 3 (21), pp. 3307-3321. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Washington, DC : American Society of Hematology, [2016]- |
| MeSH Terms: | Biomarkers* ; Disease Models, Animal*; Leukemia, Megakaryoblastic, Acute/*etiology ; Leukemia, Megakaryoblastic, Acute/*pathology ; Nuclear Pore Complex Proteins/*genetics ; Oncogene Proteins, Fusion/*genetics ; Retinoblastoma-Binding Protein 2/*genetics; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Computational Biology/methods ; Leukemia, Megakaryoblastic, Acute/therapy ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Nuclear Pore Complex Proteins/metabolism ; Oncogene Proteins, Fusion/metabolism ; Retinoblastoma-Binding Protein 2/metabolism ; Animals ; Disease Susceptibility ; Gene Expression ; Gene Expression Profiling ; High-Throughput Nucleotide Sequencing ; Humans ; Immunophenotyping ; Mice ; Xenograft Model Antitumor Assays |
| Abstract: | Acute megakaryoblastic leukemia (AMKL) represents ∼10% of pediatric acute myeloid leukemia cases and typically affects young children ( |
| References: | Hum Gene Ther. 2004 Oct;15(10):976-88. (PMID: 15585113); Nucleic Acids Res. 2017 Jul 27;45(13):e122. (PMID: 28472340); Leukemia. 2013 Dec;27(12):2280-8. (PMID: 23531517); Science. 2014 Sep 19;345(6203):1509-12. (PMID: 25237102); Blood. 2001 Jun 15;97(12):3727-32. (PMID: 11389009); Sci Signal. 2012 Oct 30;5(248):ra78. (PMID: 23112346); PLoS One. 2013 Apr 09;8(4):e60680. (PMID: 23585844); Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886); Genes Dev. 2017 Nov 15;31(22):2222-2234. (PMID: 29269482); Science. 2010 Sep 10;329(5997):1345-8. (PMID: 20688981); Cancer Cell. 2016 Dec 12;30(6):863-878. (PMID: 27889185); Leukemia. 2017 May;31(5):1166-1176. (PMID: 27780967); Leukemia. 2007 Sep;21(9):2000-9. (PMID: 17597811); Trends Cancer. 2017 Sep;3(9):631-642. (PMID: 28867167); Blood. 2014 Dec 4;124(24):3608-12. (PMID: 25339361); Eur J Haematol. 2017 Mar;98(3):218-227. (PMID: 27743390); Blood. 2015 Aug 20;126(8):943-9. (PMID: 26186939); Exp Hematol. 2017 Sep;53:26-30. (PMID: 28625745); Genes Chromosomes Cancer. 2018 Jun;57(6):311-319. (PMID: 29427526); Nat Rev Cancer. 2005 Jan;5(1):11-20. (PMID: 15630411); Int J Biochem Cell Biol. 2007;39(5):874-8. (PMID: 17137827); Cancer Cell. 2012 Nov 13;22(5):683-97. (PMID: 23153540); Leukemia. 2002 Sep;16(9):1622-6. (PMID: 12200673); Curr Hematol Malig Rep. 2016 Oct;11(5):333-41. (PMID: 27510823); Blood Adv. 2017 Sep 08;1(20):1749-1759. (PMID: 29296821); Cell Stem Cell. 2007 Aug 16;1(2):218-29. (PMID: 18371352); Cancer Cell. 2016 Nov 14;30(5):737-749. (PMID: 27846391); J Exp Med. 2012 Oct 22;209(11):2017-31. (PMID: 23045605); Nat Genet. 2017 Mar;49(3):451-456. (PMID: 28112737); BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040); Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9194-9. (PMID: 15967997); Nat Cell Biol. 2007 Jul;9(7):804-12. (PMID: 17589499); Blood Cancer J. 2017 Sep 29;7(9):e613. (PMID: 28960191); Nat Commun. 2019 May 16;10(1):2189. (PMID: 31097698); Cell Rep. 2016 Jul 12;16(2):498-507. (PMID: 27346355); Blood. 2011 Dec 8;118(24):6247-57. (PMID: 21948299); Leukemia. 2017 Mar;31(3):565-572. (PMID: 27694926); Mol Cell Biol. 2008 Nov;28(21):6668-80. (PMID: 18779318); J Clin Invest. 1989 Jul;84(1):92-9. (PMID: 2472431); Nat Med. 2018 Jan;24(1):103-112. (PMID: 29227476); Blood. 2004 Dec 1;104(12):3679-87. (PMID: 15226186); Cancer Discov. 2014 May;4(5):564-77. (PMID: 24535671); Blood. 2018 Sep 27;132(13):1399-1412. (PMID: 29898956); Nat Genet. 2019 Apr;51(4):694-704. (PMID: 30926971); Cell Stem Cell. 2014 Jan 2;14(1):94-106. (PMID: 24388174); Nat Cell Biol. 2013 Aug;15(8):916-25. (PMID: 23811688); Blood. 2016 Jun 30;127(26):3424-30. (PMID: 27114462); Leukemia. 2008 Nov;22(11):2029-40. (PMID: 18685615); Nature. 2009 Jun 11;459(7248):847-51. (PMID: 19430464) |
| Substance Nomenclature: | 0 (Biomarkers); 0 (Biomarkers, Tumor); 0 (Nuclear Pore Complex Proteins); 0 (Nup98 protein, human); 0 (Oncogene Proteins, Fusion); EC 1.14.11.- (KDM5A protein, human); EC 1.14.11.27 (Retinoblastoma-Binding Protein 2) |
| Entry Date(s): | Date Created: 20191108 Date Completed: 20200901 Latest Revision: 20240730 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6855103 |
| DOI: | 10.1182/bloodadvances.2019030981 |
| PMID: | 31698461 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't